Indaptus Therapeutics, Inc. (NasdaqCM: INDP)
Health Care · Biotechnology · US
$2.44
-2.79% today · -37.7% 1Y
Indaptus Therapeutics, Inc. (NasdaqCM: INDP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $334.44M and employs 5 people.
Over the last twelve months the share price has lost 37.7%, trading between 0.92 and 5.96.
Tweenvest scores Indaptus Therapeutics, Inc. across four factors: quality 35/100, value 91/100. Its strongest factor is value.
INDP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $334.44M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.47
- Dividend yield
- —
- Beta (5Y)
- 0.97
- 52-week high
- $5.96
- 52-week low
- $0.92
- Avg volume (3M)
- —
- Shares outstanding
- 133.24M
- Employees
- 5
- Next earnings
- —
About Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
- ISIN
- US45339J2042
- Listed since
- Aug 4, 2015
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Jiangsu Recbio Technology Co., Ltd.SEHK: 2179 | $347.01M | HK$4.42 | +0.23% |
| ROKIT Healthcare Inc.KOSDAQ: A376900 | $346.80M | ₩26,850.00 | -3.24% |
| Agenus Inc.NasdaqCM: AGEN | $345.31M | $7.47 | -2.61% |
| Artiva Biotherapeutics, Inc.NasdaqGM: ARTV | $339.30M | $6.79 | -2.16% |
| GC Corp.KOSE: A005250 | $329.56M | ₩9,750.00 | +0.72% |
| 3-D Matrix, Ltd.TSE: 7777 | $328.96M | ¥407.00 | -3.10% |
| Cabaletta Bio, Inc.NasdaqGS: CABA | $327.22M | $1.85 | -4.15% |
| Ocugen, Inc.NasdaqCM: OCGN | $324.02M | $0.95 | -0.96% |
Figures last refreshed Oct 11, 2026.